Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Biodexa Pharmaceuticals Plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001643918.
Disclosed value leader
SABBY MANAGEMENT, LLC
Comparable rows
2/10
Latest evidence
30 Jun 2026
- Public ticker
- BDRX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001643918
- Issuer location
- Cardiff
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Biodexa Pharmaceuticals Plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
SABBY MANAGEMENT, LLC
Comparable rows
2/10
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
8 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 10 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
2 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
ARMISTICE CAPITAL, LLC
10%
SABBY MANAGEMENT, LLC
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
Reported 13D/G
· 30 Jun 2026
|
$60,443
26,166 shares
|
$0 | 30 Jun 2026 |
| SABBY MANAGEMENT, LLC |
13D/G
|
9.9%
Reported 13D/G
· 31 Dec 2025
|
$493,974
217,600 shares
|
$0 | 31 Dec 2025 |
| GAMMA Investing LLC |
13F
Company
|
—
denominator unverified
|
$3,501
1,203 shares
|
— | 30 Jun 2026 |
| Simon Turton |
3/4/5
Director
|
—
denominator unverified
|
$2,377
2,765 shares
|
— | 18 Mar 2026 |
| Allied Private Wealth LLC |
13F
Company
|
—
denominator unverified
|
$1,271
489 shares
|
— | 30 Jun 2026 |
| SBI Securities Co., Ltd. |
13F
Company
|
—
denominator unverified
|
$84
29 shares
|
— | 30 Jun 2026 |
| UBS Group AG |
13F
Company
|
—
denominator unverified
|
$73
25 shares
|
— | 30 Jun 2026 |
| Hilton Head Capital Partners, LLC |
13F
Company
|
—
denominator unverified
|
$17
6 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 06 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to Biodexa Pharmaceuticals Plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
Simon Turton
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Simon Turton | Director | $2,377 | Mixed | 18 Mar 2026 | ||
| Fiona Mary Powell | Chief Financial Officer, Director | Mixed | 18 Mar 2026 | |||
| Simon de Vries | Director | Mixed | 18 Mar 2026 | |||
| Stephen Anthony Stamp | Chief Executive Officer, Director | Mixed | 18 Mar 2026 | |||
| Ann Louise Merchant | Director | Mixed | 18 Mar 2026 | |||
| Stephen Barry Parker | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Biodexa Pharmaceuticals Plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Simon Turton | BDRX | Ordinary Shares | 0 | 2,765 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.